|Dr. Randal W. Scott Ph.D.||Co-Founder & Chairman of the Board||50k||N/A||1958|
|Mr. Kenneth D. Knight||President, CEO & Director||1.4M||N/A||1961|
|Mr. Thomas R. Brida||General Counsel, Chief Compliance Officer & Secretary||776.72k||N/A||1971|
|Dr. Robert L. Nussbaum M.D.||Chief Medical Officer||751.95k||N/A||1950|
|Ms. Ana J. Schrank||Chief Accounting Officer & CFO||N/A||N/A||1966|
|Dr. David B. Sholehvar M.D.||Chief Operating Officer||N/A||N/A||1968|
|Ms. Hoki Luk||Head of Investor Relations and Capital Markets||N/A||N/A||1976|
|Ms. Shelly D. Guyer||Chief Sustainability Officer||430.44k||N/A||1960|
|Ms. Desarie French||Chief Talent Officer||N/A||N/A||N/A|
|Dr. W. Michael Korn M.D.||Chief Medical Officer||N/A||N/A||N/A|
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Invitae Corporation’s ISS Governance QualityScore as of December 1, 2023 is 9. The pillar scores are Audit: 4; Board: 10; Shareholder Rights: 7; Compensation: 9.